Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
1.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 29(3): 975-982, 2021 Jun.
Artículo en Chino | MEDLINE | ID: mdl-34105503

RESUMEN

OBJECTIVE: To analyze and predict the effect of coronavirus infection on hematopoietic system and potential intervention drugs, and explore their significance for coronavirus disease 2019 (COVID-19). METHODS: The gene expression omnibus (GEO) database was used to screen the whole genome expression data related with coronavirus infection. The R language package was used for differential expression analysis and KEGG/GO enrichment analysis. The core genes were screened by PPI network analysis using STRING online analysis website. Then the self-developed apparent precision therapy prediction platform (EpiMed) was used to analyze diseases, drugs and related target genes. RESULTS: A database in accordance with the criteria was found, which was derived from SARS coronavirus. A total of 3606 differential genes were screened, including 2148 expression up-regulated genes and 1458 expression down-regulated genes. GO enrichment mainly related with viral infection, hematopoietic regulation, cell chemotaxis, platelet granule content secretion, immune activation, acute inflammation, etc. KEGG enrichment mainly related with hematopoietic function, coagulation cascade reaction, acute inflammation, immune reaction, etc. Ten core genes such as PTPRC, ICAM1, TIMP1, CXCR5, IL-1B, MYC, CR2, FSTL1, SOX1 and COL3A1 were screened by protein interaction network analysis. Ten drugs with potential intervention effects, including glucocorticoid, TNF-α inhibitor, salvia miltiorrhiza, sirolimus, licorice, red peony, famciclovir, cyclosporine A, houttuynia cordata, fluvastatin, etc. were screened by EpiMed plotform. CONCLUSION: SARS coronavirus infection can affect the hematopoietic system by changing the expression of a series of genes. The potential intervention drugs screened on these grounds are of useful reference significance for the basic and clinical research of COVID-19.


Asunto(s)
COVID-19 , Proteínas Relacionadas con la Folistatina , Sistema Hematopoyético , Preparaciones Farmacéuticas , Biología Computacional , Humanos , SARS-CoV-2
2.
Zhongguo Ying Yong Sheng Li Xue Za Zhi ; 34(6): 530-535, 2018 Jun 08.
Artículo en Chino | MEDLINE | ID: mdl-31032588

RESUMEN

OBJECTIVE: To investigate the prognosis-related miRNA histological features and clinical significance of lung adenocarcinoma. METHODS: Using The Cancer Genome Atlas (TCGA) data, the miRNA expression profile data of human lung adenocarcinoma were searched for differential analysis, and the prognosis-related miRNAs were screened by Cox risk regression model. The targeted miRNAs were predicted by mirwalk analysis platform, KEGG functional enrichment analysis, and finally, predict the function of prognosis-related miRNAs. RESULTS: A total of 46 differential miRNAs in lung adenocarcinoma were screened, including 19 up-regulated and 27 down-regulated. Six prognostic-related miRNAs were screened by Cox survival analysis, namely hsa-mir-21, hsa-mir-142, hsa-mir-200a high expression, hsa-mir-101, hsa-let-7c, hsa-mir-378e low expression, hsa-mir-21 and hsa-mir-378e were associated with poor prognosis in patients with lung adenocarcinoma, and the survival time was shortened significantly (P<0.05, AUC=0.618). KEGG analysis showed that the above prognosis-related miRNA targeting regulatory genes were related with immune response pathways, miRNA and cancer pathways, metabolic pathways and so on. CONCLUSIONS: Hsa-mir-21 and hsa-mir-378e are associated with poor prognosis of lung adenocarcinoma, and may be used as a molecular marker for prognosis of lung adenocarcinoma after further clinical verification.


Asunto(s)
Adenocarcinoma del Pulmón , Neoplasias Pulmonares , Biomarcadores de Tumor , Biología Computacional , Regulación Neoplásica de la Expresión Génica , Humanos , MicroARNs , Pronóstico
3.
BMC Nephrol ; 18(1): 226, 2017 Jul 10.
Artículo en Inglés | MEDLINE | ID: mdl-28693441

RESUMEN

BACKGROUND: The aim of this study was to identify the optimal equation that accurately estimates the glomerular filtration rate (GFR) and the chronic kidney disease (CKD) stage in the Chinese population. METHODS: A total of 1296 Chinese patients aged 18-65 years old were enrolled in this study. The estimated GFRs (eGFRs) calculated separately by three Diet in Renal Disease (MDRD) equations and three Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations were compared with the reference GFR (rGFR) measured by the 99Tcm-DTPA renal dynamic imaging method. RESULTS: By Bland-Altman analysis, eGFRcys and eGFRscr_cys performed similarly, showing the tightest limits of agreement among the six equations. They also achieved the first and second highest 30% and 50% accuracies. Using a combination of the serum creatinine and cystatin C levels (eGFRscr_cys) could improve the bias (-0.3 for eGFRscr_cys) of the equation and achieve the highest diagnostic accuracy for renal insufficiency (AUC60, 0.953; P < 0.05, except for eGFR_MDRD). All equations predicted stage 3 CKD with moderate accuracy (49.7-51.4%) and stage 5 CKD with good accuracy (90.2-96.4%). For stage 1 CKD, eGFRcys showed a higher percentage of misclassification than the other equations. All equations seemed to perform poorly at predicting stage 2 and 4 CKD, as compared to the other CKD stages. eGFRscr_cys was the best-performing equation in terms of accurate classification of the CKD stage based on the overall performance (kappa value, 0.423). CONCLUSION: For a Chinese population, the CKD-EPIscr_cys equation seems more suitable for estimating the GFR than the other equations. Each equation had its own advantages in predicting different CKD stages.


Asunto(s)
Pueblo Asiatico/genética , Creatinina/sangre , Cistatina C/sangre , Tasa de Filtración Glomerular/fisiología , Insuficiencia Renal Crónica/sangre , Insuficiencia Renal Crónica/genética , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
4.
Indian J Med Microbiol ; 35(4): 617-619, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29405162

RESUMEN

Penicillium marneffei infection in human immunodeficiency virus (HIV)-negative patients is addressed far less often. In this article, a small cohort of HIV-negative patients who disseminated P. marneffei infection was included. Sites of infection were found from blood culture, as subcutaneous nodules, or from lymph node biopsy. Fever, rash, swollen lymph nodes, anaemia and weight loss were common characteristics in most infected patients. The signs and symptoms are diverse and create challenges for accurate diagnosis. This paper will assist our understanding of this disease and contribute to an appropriate regime of therapy, thus improving the health of P. marneffei-positive patients.


Asunto(s)
Antifúngicos/uso terapéutico , Manejo de la Enfermedad , Micosis/diagnóstico , Micosis/tratamiento farmacológico , Penicillium/aislamiento & purificación , Anciano , Sangre/microbiología , Estudios de Cohortes , Femenino , Humanos , Ganglios Linfáticos/microbiología , Masculino , Persona de Mediana Edad , Micosis/microbiología , Micosis/patología , Tejido Subcutáneo/microbiología
5.
Nan Fang Yi Ke Da Xue Xue Bao ; 36(12): 1599-1601, 2016 Dec 20.
Artículo en Chino | MEDLINE | ID: mdl-27998851

RESUMEN

OBJECTIVE: The co-occurrence of blue rubber bleb nevus syndrome (BRBNS) and ventricular septal defects is rare. Here we present a case of BRBNS in a 15-year-old boy who was born with multiple cavernous hemangiomas and a ventricular septal defect. Examinations revealed the presence of hemangioma lesions in the subcutaneous and mucosal tissues as well as in the cerebrum, nasopharynx, tongue, esophagus, gastric body, sigmoid colon and adrenal gland. Combined imaging modalities played an important role in the diagnosis of hemangioma lesions.


Asunto(s)
Neoplasias Gastrointestinales/complicaciones , Defectos del Tabique Interventricular/complicaciones , Hemangioma Cavernoso , Nevo Azul/complicaciones , Neoplasias Cutáneas/complicaciones , Adolescente , Hemangioma , Humanos , Masculino
6.
Cancer Med ; 5(8): 2012-21, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27228575

RESUMEN

Amifostine is a cytoprotective drug that was initially used to control and treat nuclear radiation injury and is currently used to provide organ protection in cancer patients receiving chemotherapy. Clinical studies have also found that amifostine has some efficacy in the treatment of cytopenia caused by conditions such as myelodysplastic syndrome and immune thrombocytopenia, both of which involve megakaryocyte maturation defects. We hypothesized that amifostine induced the differentiation of megakaryocytes and investigated this by exposing the human Dami megakaryocyte leukemia cell line to amifostine (1 mmol/L). After 12 days of amifostine exposure, optical microscopy showed that the proportion of Dami cells with diameters >20 µm had increased to 24.63%. Transmission electron microscopy identified the development of a platelet demarcation membrane system, while flow cytometry detected increased CD41a expression and decreased CD33 expression on the Dami cell surface. Ploidy analysis found that the number of polyploid cells with >4N DNA content increased to 27.96%. We did not detect any elevation in the mRNA or protein levels of megakaryocytic differentiation-associated transcription factors GATA-binding factor 1 (GATA-1) and nuclear factor, erythroid 2 (NF-E2), but nuclear import assay revealed an increased nuclear translocation of these proteins. These findings indicate that amifostine induced the differentiation of Dami cells into mature megakaryocytes via a mechanism involving increased nuclear translocation of the transcription factors, NF-E2 and GATA-1.


Asunto(s)
Amifostina/farmacología , Diferenciación Celular/efectos de los fármacos , Células Progenitoras de Megacariocitos/citología , Células Progenitoras de Megacariocitos/efectos de los fármacos , Megacariocitos/citología , Megacariocitos/efectos de los fármacos , Biomarcadores , Diferenciación Celular/genética , Línea Celular , Proliferación Celular/efectos de los fármacos , Citoprotección , Humanos , Inmunofenotipificación , Megacariocitos/metabolismo , Poliploidía , Factores de Transcripción/genética , Factores de Transcripción/metabolismo
7.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 22(1): 58-63, 2014 Feb.
Artículo en Chino | MEDLINE | ID: mdl-24598652

RESUMEN

This study was purposed to evaluate the effectiveness and safety of autologous cytokine induced killer (CIK) cells combined with chemotherapy in treatment of elderly patients with acute myeloid leukemia. Peripheral blood mononuclear cells (PBMNC) were isolated from 5 elderly patients with acute myeloid leukemia, and then augmented by priming with interferon gamma (IFN-γ) followed by IL-2 and monoclonal antibody (mAb) against CD3. The autologous CIK cells thus obtained were infused back to individual patients, 28 days as one cycle. The changes in cellular immune function, incidence of infection, independence of hematoglobin or blood transfusion, and progression of disease were observed and assessed before and after therapy. The results showed that the 46 cycles of CIK cell infusion were performed for 5 patients, no adverse reaction was observed in these patients. The percentages of CD3(+), CD3(+)CD8(+) and CD3(+)CD56(+) increased significantly (P < 0.05), The therapy of CIK could significantly reduce the incidence of infection (P < 0.05) and shorten the time of high fever in AML patients (P < 0.05). CIK also could reduce the volume of erythrocyte infusion to maintenance hematoglobin level (P < 0.05). We found that although CIK could not change the outcome of AML, the combination of CIK and chemotherapy could control patients' condition and prolong their survival during the development and end stage of AML. It is concluded that autologous CIK cells combined with chemotherapy is safe and efficacious for the elderly patients with acute myeloid leukemia.


Asunto(s)
Células Asesinas Inducidas por Citocinas , Leucemia Mieloide Aguda/terapia , Anciano , Anciano de 80 o más Años , Terapia Combinada , Humanos , Leucemia Mieloide Aguda/tratamiento farmacológico , Masculino
8.
Cytotherapy ; 16(2): 278-84, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24438905

RESUMEN

BACKGROUND AIMS: Currently available treatment methods for advanced plasmacytoma include surgery, chemotherapy, radiotherapy, immunomodulatory agents, hematopoietic stem cell transplantation and donor lymphocyte infusion. We report a case of advanced refractory multiple solitary plasmacytomas in a 68-year-old Asian man with multiple bone lesions, in whom autologous cytokine-induced killer (CIK) cells were administered in an effort to eliminate residual tumor lesions. METHODS: CIK cells were infused monthly for 21 courses. RESULTS: The patient has survived 63 months since the first hospital visit without disease progression for 40 months. CONCLUSIONS: This case represents the first report of autologous CIK cell immunotherapy used successfully to suppress multiple solitary plasmacytomas and resolve bone lesions.


Asunto(s)
Neoplasias Óseas/terapia , Vacunas contra el Cáncer , Células Asesinas Inducidas por Citocinas/trasplante , Trasplante de Células Madre Hematopoyéticas , Inmunoterapia/métodos , Plasmacitoma/terapia , Anciano , Pueblo Asiatico , Neoplasias Óseas/inmunología , Células Asesinas Inducidas por Citocinas/inmunología , Supervivencia sin Enfermedad , Humanos , Masculino , Plasmacitoma/inmunología , Trasplante Autólogo
10.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 21(6): 1464-70, 2013 Dec.
Artículo en Chino | MEDLINE | ID: mdl-24370030

RESUMEN

The purpose of this study was to explore the clinicopathological features, therapy and prognostic factors of elderly patients with non-Hodgkin's lymphoma (NHL). The clinical data including general clinical characteristics, pathological features, chemotherapy selection and treatment response of 30 patients with NHL in our hospital from January 2003 to December 2012 were analyzed retrospectively. The survival was analyzed by using Kaplan-Meier methods, and the prognosis was evaluated by COX regression multivariate analysis model. The clinical parameters selected include age, Ann Arbor stage, international prognostic index (IPI), B symptom and lactate dehydrogenase (LDH) levels. The results showed that all the patients suffered from underlying disease, and the cardiovascular disease (hypertension, coronary heart disease, arrhythmia) is the most common, and minority (8/30) combined with secondary tumor, the 63% (19/30) cases had B symptoms at diagnosis. only 2 cases were diagnosed as T-cell lymphoma; the 93% (28/30) cases combined with B-cell lymphoma, 57% (17/28) of them combined with diffuse large B-cell lymphoma. Ann-Arbor stage ≤ IIwas 37% (11/30);10(37%) patient's IPI score was ≤ 2, and 67% (20/30) was scored 3-5; 13(43%) patient's serum LDH level was abnormal. Modified R-CHOP chemotherapy was given individually on the basis of clinical features. The patients achieved complete remission, partial remission, stable disease, or progressive disease accounted for 14 (46.7%), 13 (43.3%), 1 (3.3%), and 2 (6.7%), respectively; the total reaction rate was 90% after 4 cycles of chemotherapy; the overall survival (OS) rate at 1 and 2 years was 73.3% and 43.3%, and progression-free survival (PFS)rate at 0.5 and 1 years was 62.2% and 54.9%; multivariate analysis by COX regression showed that B symptoms and Ann-Arbor stage were independent factors (P = 0.014, 0.039; RR = 6.678, 4.939, respectively) affecting the OS of elderly NHL, and IPI score affected PFS independently. It is concluded that elderly patients with NHL usually are of late stage at newly diagnosis and have suffered from underlaying diseases. Besides strengthening supportive treatment, modified R-CHOP chemotherapy should be given individually according to different prognosis. B symptoms and Ann-Arbor stage >II are indicators for poor prognosis of elderly NHL.


Asunto(s)
Linfoma no Hodgkin/patología , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/terapia , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Resultado del Tratamiento
11.
PLoS One ; 8(5): e64354, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23691202

RESUMEN

BACKGROUND: In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM). Herein, we report results of a meta-analysis of RCTs examining the efficacy and safety of lenalidomide for MM. PATIENTS AND METHODS: Databases were searched using the terms "lenalidomide or revlimid AND multiple myeloma."RCTs evaluating initial or maintenance therapeutic outcomes were included. Main outcome measures were response rates, progression-free survival (PFS), overall survival, and adverse events. RESULTS: Seven trials were included (N = 192-614 participants). Lenalidomide doses and treatment regimens differed between trials. Complete response (CR) and very good partial response (VGPR) risk ratios (RR) favored lenalidomide over placebo (CR = 2.54, 95% confidence interval [CI] = 1.29-5.02; VGPR = 2.82, 95% CI = 1.30-6.09). The PFS hazard ratio favored lenalidomide over placebo (0.37, 95% CI = 0.33-0.41). For adverse events, neutropenia, deep vein thrombosis (DVT), infection, and hematologic cancer RR favored placebo over lenalidomide (neutropenia: 4.74, 95% CI = 2.96-7.57; DVT: 2.52; 95% CI: 1.60-3.98; infection: 1.98; 95% CI: 1.50-2.62; hematologic cancer: 3.20; 95% CI: 1.28-7.98). CONCLUSIONS: Lenalidomide is an effective treatment for MM; however, treatment-related adverse events must be considered and appropriate adjustments and/or prophylactic treatment should be initiated where possible.


Asunto(s)
Mieloma Múltiple/tratamiento farmacológico , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Talidomida/análogos & derivados , Supervivencia sin Enfermedad , Humanos , Lenalidomida , Neoplasias Primarias Secundarias , Talidomida/efectos adversos , Talidomida/uso terapéutico , Resultado del Tratamiento
12.
Hematol Oncol ; 30(3): 115-22, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22972689

RESUMEN

The elderly population is susceptible to haematological malignancies, and these elderly patients are intolerant to cytotoxic drugs. Therefore, the exploration of a safe and reliable strategy exclusive of chemotherapy is critical in improving the prognosis of elderly patients with haematological malignancies. We evaluated the safety and the efficacy of autologous cytokine-induced killer (CIK) cells combined with recombinant human interleukin 2 (rhIL-2) in the treatment of haematological malignancies in elderly patients. Peripheral blood mononuclear cells were isolated from 20 elderly patients with haematological malignancies, then augmented by priming with interferon gamma, rhIL-2 and CD3 monoclonal antibody. The autologous CIK cells (2-3 × 10(9)) were transfused back to patients, followed by a subcutaneous injection of IL-2 (1 mU/day) for 10 consecutive days. The regimen was repeated every 4 weeks. The host cellular immune function, tumour-related biological parameters, imaging characteristics, disease condition, quality of life and survival time were assessed. Fourteen patients received 8 cycles of transfusion and 6 received 4 cycles. No adverse effects were observed. The percentages of CD3(+), CD3(+) CD8(+) and CD3(+) CD56(+) cells were significantly increased (p < 0.05), and the levels of serum ß2 microglobulin and lactate dehydrogenase (LDH) were markedly decreased (p < 0.05) after autologous CIK cell transfusion. Cancer-related symptoms were profoundly alleviated, as demonstrated by the improved quality of life (p < 0.01). Complete remission was observed in 11 patients, persistent partial remission in 7 patients and stable disease in 2 patients. At the end of follow-up, the mean survival time was 20 months. Transfusion with autologous CIK cells plus rhIL-2 treatment is safe and effective for treating haematological malignancies in elderly patients.


Asunto(s)
Células Asesinas Inducidas por Citocinas/trasplante , Neoplasias Hematológicas/cirugía , Inmunoterapia Adoptiva , Síndromes Mielodisplásicos/cirugía , Terapia Recuperativa , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor , Células Cultivadas/efectos de los fármacos , Células Cultivadas/trasplante , Comorbilidad , Femenino , Neoplasias Hematológicas/tratamiento farmacológico , Humanos , Interferón gamma/farmacología , Interleucina-2/farmacología , Interleucina-2/uso terapéutico , L-Lactato Deshidrogenasa/sangre , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Leucemia Linfocítica Crónica de Células B/cirugía , Linfoma no Hodgkin/tratamiento farmacológico , Linfoma no Hodgkin/cirugía , Masculino , Persona de Mediana Edad , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/cirugía , Síndromes Mielodisplásicos/tratamiento farmacológico , Proyectos Piloto , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/uso terapéutico , Inducción de Remisión , Timopentina/farmacología , Timopentina/uso terapéutico , Resultado del Tratamiento , Microglobulina beta-2/análisis
13.
PLoS One ; 7(7): e41467, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22848504

RESUMEN

BACKGROUND: Human xenograft models, resulting from orthotopic transplantation (implantation into the anatomically correct site) of histologically intact tissue into animals, are important for investigating local tumor growth, vascular and lymphatic invasion at the primary tumor site and metastasis. METHODOLOGY/PRINCIPAL FINDINGS: We used surgical orthotopic transplantation to establish a nude mouse model of primary hepatic lymphoma (PHL), HLBL-0102. We performed orthotopic transfer of the HLBL-0102 tumor for 42 generations and characterized the tumor cells. The maintenance of PHL characteristics were supported by immunohistochemical and cytogenetic analysis. We also report the antitumor effect of Cantide, an antisense phosphorothioate oligonucleotide against hTERT, on the growth of HLBL-0102 tumors. We showed a significant, dose-dependent inhibition of tumor weight and serum LDH activity in the orthotopically transplanted animals by Cantide. Importantly, survival was prolonged in Cantide-treated HLBL-0102 tumor-bearing mice when compared to mock-treated mice. CONCLUSIONS/SIGNIFICANCE: Our study provided the basis for the development of a clinical trial protocol to treat PHL.


Asunto(s)
Neoplasias Hepáticas/tratamiento farmacológico , Linfoma de Células B/tratamiento farmacológico , Proteínas de Neoplasias/antagonistas & inhibidores , Oligonucleótidos Fosforotioatos/farmacología , Telomerasa/antagonistas & inhibidores , Ensayos Antitumor por Modelo de Xenoinjerto , Animales , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Neoplasias Hepáticas/enzimología , Neoplasias Hepáticas/patología , Linfoma de Células B/enzimología , Linfoma de Células B/patología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Proteínas de Neoplasias/metabolismo , Trasplante de Neoplasias , Telomerasa/metabolismo , Trasplante Heterólogo
14.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 20(3): 564-70, 2012 Jun.
Artículo en Chino | MEDLINE | ID: mdl-22739156

RESUMEN

This study was purposed to evaluate the safety and curative effect of autologous cytokine induced killer cells (CIK) combined with low-dose IL-2 regimen containing immune enhancement of thymic peptide on elderly patients with B-cell chronic lymphocytic leukemia (B-CLL). Thymic peptide α1 was subcutaneously given as the immunoenhancement agent at a dose of 1.6 mg/d, 14 days as one cycle. Peripheral blood mononuclear cells (PBMNC) from 5 patients with B-CLL were isolated once a week to induce ex vivo CIK cells through culture in the context of interferon (IFN)-γ, interleukin (IL)-2 and anti-CD3 monoclonal antibody. The PBMNC were separated from patients before and after 14 days as one cycle of thymic peptide α1 administration. Parameters of amplification ability, effector cells quantity, lymphocyte subgroups percentage and antitumor cytotoxicity were compared before and after thymic peptide administration. The 5 patients were treated with CIK cells combined with low-dose IL-2 regimen immediately after injection of thymic peptide α1. The CIK cells plus low-dose IL-2 regimen containing thymic peptide enhancement was defined as: thymic peptide α1 1.6 mg/d was subcutaneously administered once every other day; (4 - 6) ×10(9) of CIK cells were transfused followed by IL-2 subcutaneous administration of 1 mU/d on days 1-10, 28 days as one cycle. Clinical evaluation parameters including cellular immunity function, CLL related biomarkers, disease state and infectious frequency and degree were investigated before and after CIK cells infusion puls IL-2. The results showed that the amount of amplified CIK cells, the percentage and amplification times of effector cells and antitumor cytotoxicity more significantly increased after thymic peptide α1 treatment than before its use (P < 0.05). The total 46 cycles of CIK cells infusion plus IL-2 were completed in the 5 CLL patients. No adverse reaction was observed. After treatment of CIK cells plus IL-2, the general conditions of 5 CLL patients were to different extent improved. Simultaneously, percentages of CD3(+), CD3(+)CD8(+), and CD3(+)CD56(+) cells in peripheral blood remarked by raised (P < 0.05), the serum level of ß2 microglobulin was significantly declined (P < 0.05), and the frequency and degree of infection was also decreased (P < 0.05). Following CIK cells plus IL-2 therapy, the transformation of disease state from partial remission (PR) to complete remission was seen in 3 patients, from stable disease (SD) to PR in 1 patient, and from progress of disease to SD in 1 patient. It is concluded that the regimen of autologous CIK cells combined with low-dose IL-2 containing immune enhancement of thymic peptide is safety and effective for the treatment of elderly patients with B-CLL.


Asunto(s)
Células Asesinas Inducidas por Citocinas/inmunología , Leucemia Linfocítica Crónica de Células B/terapia , Timosina/inmunología , Anciano , Anciano de 80 o más Años , Humanos , Interleucina-2/administración & dosificación , Interleucina-2/uso terapéutico , Masculino
15.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 20(3): 782-7, 2012 Jun.
Artículo en Chino | MEDLINE | ID: mdl-22739202

RESUMEN

The function of immune system degenerates in an aging-dependent manner and this results in immunosenescence. Human immune system includes two parts: genetic/innate immunity and adaptive immunity. The former is involved in monocytes, nature killer cells, and dendritic cells, the later is involved in acquired B and T lymphocytes. During the aging of immunity system, the both parts of immunity are damaged to some degree. Generally, innate immunity seems well-retained and the acquired immunity is degenerative seriously with aging. Immunocyte senescence is closely related to the elderly decreased ability to control infectious disease, cancer and to their generally poor response to vaccination. This review summarized the research progress on immunosenescence characteristics in aged phase.


Asunto(s)
Envejecimiento/inmunología , Formación de Anticuerpos , Inmunidad Celular , Factores de Edad , Formación de Anticuerpos/inmunología , Senescencia Celular , Humanos , Inmunidad Celular/inmunología , Activación de Linfocitos
16.
Am J Med Sci ; 343(4): 337-41, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22270402

RESUMEN

Acute tumor lysis syndrome (ATLS) is a recognized complication of the treatment of malignant lymphomas and is associated with significant morbidity and mortality. However, there have been few reports of the occurrence of ATLS in patients treated with rituximab. This study reports 2 patients with high-grade diffuse large B-cell non-Hodgkin's lymphoma who presented high tumor load, were sensitive to treatment and had multiple risk factors for ATLS. Both patients developed ATLS after treatment with rituximab and, despite aggressive supportive therapy, died of multiple organ failure. These cases illustrate that ATLS can occur after treatment with rituximab and that a high index of suspicion is necessary for the prompt diagnosis of ATLS.


Asunto(s)
Anticuerpos Monoclonales de Origen Murino/efectos adversos , Linfoma de Células B Grandes Difuso/diagnóstico , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Síndrome de Lisis Tumoral/diagnóstico , Síndrome de Lisis Tumoral/etiología , Anciano , Anciano de 80 o más Años , Humanos , Masculino , Rituximab , Resultado del Tratamiento
17.
Cell Biochem Biophys ; 62(1): 257-65, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21913005

RESUMEN

To evaluate the effectiveness and safety of autologous cytokine-induced killer (CIK) cells in elderly patients with diffuse large B-cell lymphoma. Peripheral blood mononuclear cells (PBMC) were isolated from nine elderly patients with diffuse large B-cell lymphoma. PBMCs were augmented by priming with interferon gamma (IFN-γ) followed by IL-2 and monoclonal antibody (mAb) against CD3. Autologous CIK cells (range 5 × 10(9)-1 × 10(10)) were then infused back to individual patients; infusion was repeated every 4 weeks for 32 weeks (eight cycles). Patients were assessed for changes in lymphocyte subgroup, tumor-related biological parameters, imaging characteristics, the condition of remission, quality of life (QOL), and survival. Prior to CIK infusion, two patients were in complete remission and seven patients were in partial remission. After autologous CIK cell transfusions, the proportion of CD3+, CD3+CD8+, and CD3+CD56+ cells were significantly increased compared with baseline (P < 0.05); whereas serum levels of ß2-microglobulin and LDH were significantly decreased (P < 0.05). The lymphoma symptoms were reduced and QOL was improved (P < 0.05) in all patients. All patients achieved complete remission at study endpoint. No adverse reactions were reported. Autologous CIK cell immunotherapy is safe and efficacious for the treatment of elderly patients with diffuse large B-cell lymphoma.


Asunto(s)
Células Asesinas Inducidas por Citocinas/trasplante , Inmunoterapia , Linfoma de Células B Grandes Difuso/terapia , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/farmacología , Complejo CD3/inmunología , Complejo CD3/metabolismo , Antígeno CD56/metabolismo , Antígenos CD8/metabolismo , Células Cultivadas , Células Asesinas Inducidas por Citocinas/inmunología , Femenino , Humanos , Interferón gamma/farmacología , Interleucina-2/farmacología , L-Lactato Deshidrogenasa/sangre , Linfoma de Células B Grandes Difuso/diagnóstico por imagen , Linfoma de Células B Grandes Difuso/metabolismo , Linfoma de Células B Grandes Difuso/mortalidad , Macroglobulinas/análisis , Masculino , Persona de Mediana Edad , Imagen Multimodal , Tomografía de Emisión de Positrones , Análisis de Supervivencia , Tomografía Computarizada por Rayos X , Trasplante Autólogo , Resultado del Tratamiento
18.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 19(3): 711-6, 2011 Jun.
Artículo en Chino | MEDLINE | ID: mdl-21729556

RESUMEN

Objective of this study was to perform bioinformatics analysis of the characteristics of gene expression profiling regulated by amifostine and predict its novel potential biological function to provide a direction for further exploring pharmacological actions of amifostine and study methods. Amifostine was used as a key word to search internet-based free gene expression database including GEO, affymetrix gene chip database, GenBank, SAGE, GeneCard, InterPro, ProtoNet, UniProt and BLOCKS and the sifted amifostine-regulated gene expression profiling data was subjected to validity testing, gene expression difference analysis and functional clustering and gene annotation. The results showed that only one data of gene expression profiling regulated by amifostine was sifted from GEO database (accession: GSE3212). Through validity testing and gene expression difference analysis, significant difference (p < 0.01) was only found in 2.14% of the whole genome (460/192000). Gene annotation analysis showed that 139 out of 460 genes were known genes, in which 77 genes were up-regulated and 62 genes were down-regulated. 13 out of 139 genes were newly expressed following amifostine treatment of K562 cells, however expression of 5 genes was completely inhibited. Functional clustering displayed that 139 genes were divided into 11 categories and their biological function was involved in hematopoietic and immunologic regulation, apoptosis and cell cycle. It is concluded that bioinformatics method can be applied to analysis of gene expression profiling regulated by amifostine. Amifostine has a regulatory effect on human gene expression profiling and this action is mainly presented in biological processes including hematopoiesis, immunologic regulation, apoptosis and cell cycle and so on. The effect of amifostine on human gene expression need to be further testified in experimental condition.


Asunto(s)
Amifostina/farmacología , Biología Computacional , Perfilación de la Expresión Génica/métodos , Expresión Génica/efectos de los fármacos , Humanos , Análisis por Micromatrices , Anotación de Secuencia Molecular
19.
Zhonghua Wei Chang Wai Ke Za Zhi ; 14(5): 352-5, 2011 May.
Artículo en Chino | MEDLINE | ID: mdl-21614690

RESUMEN

OBJECTIVE: To evaluate the accuracy of sentinel lymph node mapping(SLM) in patients with rectal cancer by single-photon emission computed tomography (SPECT-CT) lymphoscintigraphy and carbon nanoparticles suspension injection. METHODS: Twelve patients with clinical T(1-2)N(0)M(0) rectal cancer were selected and locally injected with technetium-(99m)sulfur-colloid and carbon nanoparticles suspension by endoscope one day before surgery, followed by SPECT-CT scanning 1, 3 and 5 hours later. Radioactive isotope(RI) uptake of each sentinel node(SN) basin with location preoperatively determined by SPECT-CT was postoperatively calculated using gamma probe. Nodes with the highest RI uptake, the number of which was also pre-determined by SPECT-CT, was defined as SNs. Immunohistochemical cytokeratin staining was performed for all the SNs and non-SNs. RESULTS: The rate of sentinel node detection was 91.7%(11/12) with at least one SN(1-3) per patient. Ten cases showed metastasis-negative in SNs as well as all the resected regional nodes by immunohistochemical cytokeratin staining. Only one patient had positive nodes in both SN and non-SNs. The accuracy of SLM was 100%. CONCLUSION: SPECT-CT lymphoscintigraphy and carbon nanoparticles suspension injection can effectively detect the anatomic location and number of sentinel nodes, and improve the accuracy of SLM for rectal cancer.


Asunto(s)
Neoplasias del Recto/diagnóstico , Biopsia del Ganglio Linfático Centinela/métodos , Tomografía Computarizada de Emisión de Fotón Único/métodos , Adulto , Anciano , Carbono , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nanoestructuras , Neoplasias del Recto/diagnóstico por imagen , Neoplasias del Recto/patología , Tomografía Computarizada por Rayos X/métodos
20.
Nan Fang Yi Ke Da Xue Xue Bao ; 30(12): 2643-5, 2010 Dec.
Artículo en Chino | MEDLINE | ID: mdl-21177168

RESUMEN

OBJECTIVE: To synthesize the complex fac-[99(m)Tc(CO)3(H2O)3](+) for labeling IgG and investigate the in vitro stability of 99(m)Tc(CO)3(H2O)3-IgG and its biodistribution in mice. METHODS: fac-[99(m)Tc(CO)3(H2O)3](+) was synthesized and its radiochemical purity determined using polyamide membrane chromatography. IgG was directly labeled with fac-[99(m)Tc(CO)3(H2O)3](+) and the labeling ratio was determined using chromatography. The stability of 99(m)Tc(CO)3(H2O)3-IgG in human serum albumin and normal saline was evaluated. 99(m)Tc(CO)3(H2O)3-IgG was injected via the tail vein into 9 mice at the dose of 3.7×104 Bq/100 µl, and SPECT image was obtained at 2, 4 and 12 h after the injection. The mice were sacrificed at these time points to measure the radioactivity and calculate the %ID/g in each organ. RESULTS: Fac-[99(m)Tc(CO)3(H2O)3](+) had a radiochemical purity of 82.48% and remained stable in vitro at room temperature within 4 h. The labeling ratio of 99(m)Tc(CO)3(H2O)3-IgG was 57.04% with a radiochemical purity exceeding 90%. In the solution of human serum albumin, the labeled IgG maintained a stable radiochemical purity, but in normal saline, its radiochemical purity was lowered to 20% at 24 h. After injection in mice, the labeled IgG was deposited mainly in the liver, spleen, kidneys, and the blood pool showed a sustained radioactivity. CONCLUSION: 99(m)Tc(CO)3(H2O)3-IgG prepared in this study has good stability in vitro and in vivo in 24 h and shows a biodistribution pattern similar to that of IgG protein in vivo. The intermediate fac-[99(m)Tc(CO)3(H2O)3](+) can meet the experimental requirement for labeling monoclonal antibodies and polypeptides.


Asunto(s)
Inmunoglobulina G/metabolismo , Compuestos de Organotecnecio/farmacocinética , Radiofármacos/farmacocinética , Animales , Inmunoglobulina G/administración & dosificación , Ratones , Ratones Endogámicos , Distribución Tisular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...